Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LW1646
- Development stage
- Preclinical
- Lead developer
- Sun Yat-sen University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LW1646 is a newly synthesized, highly specific, and potent phosphodiesterase 5 (PDE5) inhibitor. Developed by researchers at Sun Yat-sen University and Hainan University, LW1646 is being investigated for its therapeutic potential in chronic kidney disease, specifically in ameliorating renal fibrosis and lipid-induced kidney injuries. Mechanistically, LW1646 activates the cGMP/PKG signaling pathway, which alleviates endoplasmic reticulum (ER) stress, maintains mitochondrial homeostasis, and inhibits the formation of mitochondria-associated membranes (MAMs), thereby reducing mitochondrial calcium overload and preventing the progression of kidney fibrosis.
02
Targets
PDE5 (Phosphodiesterase 5A)
Beyond the preview
Go deeper on LW1646.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LW1646.